Vai alla homepage
4.6/5
TrustPilot

I migliori medici di Chemioterapia per il cancro al fegato in Turchia — TOP-19 medici

Confronta i migliori medici di Chemioterapia per il cancro al fegato e i prezzi in Turchia. Trova qui la tua scelta ideale.

Richiedi preventivi da 3 migliori specialisti di Chemioterapia per il cancro al fegato in Turchia

Selezioneremo i migliori medici in base alle tue esigenze e al tuo budget.

Medici top

19

Turchia

Recensioni

14000+

Da pazienti reali

Scegli il paese con i migliori prezzi per i servizi medici

Confronta i prezzi di Chemioterapia per il cancro al fegato nei principali paesi

Tocca un paese per vedere i migliori medici e i prezzi

Spain
Germany
Turkey
South Korea
$500 - $4,700
$1,100 - $1,200
$1,800 - $6,000
$3,000 - $3,000
$0
$1,000
$2,000
$3,000
$4,000
$5,000
$6,000

Quanto pagano davvero i pazienti Bookimed per Chemioterapia per il cancro al fegato in Turchia

Gamma più richiesta

$3K

$4.5K

$6K+

$9K+

$12K+

$2,800 – $6,000

La maggior parte dei pazienti paga in questa fascia

Il costo esatto dipende dal medico scelto, dalla tecnica, dalle aree trattate e dalle tue esigenze individuali.

Ottieni un preventivo preciso per il tuo caso.

Ricevi piani di trattamento personalizzati gratuiti e scegli l'opzione migliore. Nessun impegno · Nessun costo per i nostri servizi

Mostra prima:

141 persone hanno richiesto un preventivo lo scorso mese

Bulent Karagoz

  • Medico leader per Chemioterapia per il cancro al fegato
  • 5 Eccellente 4 recensioni
  • 33 anni di esperienza
  • Località: Turchia, Istanbul
  • Il medico è un oncologo medico turco altamente esperto, specializzato in sarcoma, linfoma, cancro al pancreas, polmone e seno. Con oltre 20 anni di esperienza, il medico si concentra sulla biologia dei tumori, l'immunologia dei tumori, l'immunoterapia del cancro e le terapie mirate. Dal 2019, il medico lavora come oncologo medico presso il Centro Medico Anadolu e ha precedentemente ricoperto ruoli di leadership presso la Facoltà di Medicina dell'Università Okan di Istanbul e l'Ospedale di Formazione GATA Haydarpaşa. Il medico è autore di oltre 40 pubblicazioni nella ricerca sul cancro ed è membro dell'Associazione Turca di Oncologia Medica e della Società Europea di Testa e Collo.<\/p>

  • Mostra di più
Prezzo del pacchetto da$1,800

55 persone hanno richiesto un preventivo lo scorso mese

Eda Tanrikulu

  • 5 Eccellente 2 recensioni
  • 21 anni di esperienza
  • Località: Turchia, Istanbul
  • La Dott.ssa Eda Tanrikulu è specializzata in oncologia medica e chemioterapia presso l'Anadolu Medical Center, con un focus sul cancro al fegato.

    • Ha completato la formazione in oncologia medica presso l'Università di Marmara
    • Ha lavorato come ricercatrice principale in studi clinici internazionali
    • Precedentemente responsabile dell'unità di oncologia medica presso l'Ospedale di Formazione e Ricerca Haydarpaşa Numune
    • Classificata al 3° posto in Turchia nell'esame per sottospecialità
  • Mostra di più
Prezzo del pacchetto da$1,800

32 persone hanno richiesto un preventivo lo scorso mese

Mustafa Solak

  • 5 Eccellente 1 recensioni
  • 20 anni di esperienza
  • Località: Turchia, Istanbul
  • Il Dr. Solak è specializzato in tumori gastrointestinali, incluso il cancro al fegato, con una formazione di fellowship presso l'Istituto dei Tumori dell'Università di Hacettepe.

    • Esperto nel trattare tumori al seno, testicolari, ovarici, polmonari e della testa-collo
    • Formazione presso il MD Anderson Cancer Center dell'Università del Texas
    • Lavora presso l'Hisar Hospital Intercontinental
  • Mostra di più
Visita dal medico
Prezzo su richiesta

Abdullah Sakin

  • 19 anni di esperienza
  • Località: Turchia, Istanbul
  •  

    Experience

    2022 PRIVATE MEDIPOL BAHÇELİEVLER HOSPITAL

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital, Medical Oncology Clinic Education Officer

     

    2021 - 2021 Prof. Dr. Cemil Taşçıoğlu City Hospital

     

    2020 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2020 - 2021 Head of the Department of Medical Oncology, Yüzüncü Yıl University Faculty of Medicine, Assoc. Dr.  

     

    2018 - 2021 Lecturer - Yüzüncü Yıl University Faculty of Medicine, Head of Medical Oncology Department  

     

    2018 - 2021 Yüzüncü Yıl University Faculty of Medicine

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital

     

    2015 - 2018 University of Health Sciences, Okmeydanı Training and Research Hospital, Medical Oncology Clinic, Sub-branch assistant

     

    2012 - 2015 Kanuni Sultan Süleyman Training and Research Hospital, Internal Medicine specialist

     

    2012 - 2015 Suleiman the Magnificent Training and Research Hospital,

     

    2008 - 2012 Haseki Training and Research Hospital

     

    2006 - 2008 Kızıltepe No. 3 Health Center General Practitioner.

     

     

    Education

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2018

    İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji, İstanbul Okmeydanı Eğitim ve Araştırma Hastanesi, Tıbbı Onkoloji

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları, İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2012

    İstanbul Haseki Eğitim ve Araştırma Hastanesi, İç Hastalıkları

    2007

    Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi, Uludağ Üniversitesi Tıip Fakültesi, Tıip Fakültesi

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta

44 persone hanno richiesto un preventivo lo scorso mese

Sinan Karaaslan

  • 5 Eccellente 1 recensioni
  • 29 anni di esperienza
  • accreditamenti:
  • Località: Turchia, Istanbul
  • Il medico è specializzato nella gestione del cancro al seno, del colon-retto e dei tumori del sistema urogenitale. Con un'ampia esperienza dal 2014 presso l'Anadolu Medical Center, il medico ha precedentemente lavorato presso il Medical Park Hospital, l'Ospedale di Educazione e Ricerca Kocaeli Derince e l'Ospedale Regionale di Educazione e Ricerca di Erzurum. Il servizio militare del medico includeva un ruolo come specialista in Oncologia Medica presso l'Accademia Medica Militare di Gülhane.<\/p>

    I successi educativi includono una laurea in medicina generale presso l'Università di Istanbul e specializzazioni in medicina interna e oncologia medica. Il medico è membro dell'Associazione Medica Turca, della Società Turca di Oncologia Medica e della Società Turca di Cancro del Polmone.<\/p>

  • Mostra di più
Prezzo del pacchetto da$1,800

Yesim Yildirim

  • 5 Eccellente 10 recensioni
  • 22 anni di esperienza
  • accreditamenti:
  • Località: Turchia, Istanbul
  • La professoressa Yesim Yildirim è un'esperta di punta nell'immunoterapia contro il cancro e nelle terapie mirate, con oltre 12 anni di esperienza presso il Centro Medico Anadolu.

    • Specializzata in tumori della mammella, gastrointestinali e polmonari
    • Ha pubblicato oltre 80 articoli di oncologia a livello internazionale e nazionale
    • Membro dell'ESMO e dell'ESO, con certificazione da parte dell'ESMO
    • Professoressa presso l'Università di Haliç, contribuendo all'istruzione in oncologia
    • Formata presso istituzioni prestigiose tra cui il Rambam Medical Centre e il Mount Vernon Cancer Center
  • Mostra di più
Prezzo del pacchetto da$1,800

Dr. Sezer Saglam

  • 5 Eccellente 1 recensioni
  • 29 anni di esperienza
  • accreditamenti:
  • Località: Turchia, Istanbul
  • Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

    Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Necdet Uskent

  • 55 anni di esperienza
  • Località: Turchia, Istanbul
  • Il medico si è laureato presso la Facoltà di Medicina dell'Università di Ankara e ha completato la formazione in medicina interna presso la Scuola di Medicina di Ankara GATA. Specializzandosi in oncologia medica e ematologia, il medico ha completato una borsa di studio clinica negli Stati Uniti. Pioniere in Turchia, il medico ha fatto parte del team che ha eseguito il primo trapianto di midollo osseo nel paese. Il medico ha servito come docente ospite in istituzioni prestigiose a Londra e in Svizzera. In possesso del Certificato Europeo di Oncologia Medica, il medico è membro fondatore sia della Società Turca di Oncologia Medica che del Gruppo Oncologico Turco. Il focus clinico include tumori al seno, gastrointestinali, polmonari, linfomi e mieloma.<\/p>

  • Mostra di più
Prezzo del pacchetto da$1,800

Mustafa Serkan Alemdar

  • 20 anni di esperienza
  • Località: Turchia, Adalia
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • Mostra di più
Visita dal medico
Prezzo su richiesta

Tahsin Ozatli

  • 2016 anni di esperienza
  • Località: Turchia, Istanbul
  • Il medico è un oncologo specializzato nel trattamento dei tumori al seno, ai polmoni e gastrointestinali. Attualmente, il medico pratica presso l'Ospedale Universitario Istinye Liv.

    Con una carriera che si estende su molteplici istituzioni prestigiose, il medico ha servito come Specialista in Medicina Interna presso l'Ospedale Statale di Malatya, medico presso la Clinica Oncologica di Ankara e membro del Dipartimento di Oncologia presso l'Ospedale Regionale di Formazione e Ricerca di Erzurum.

    Il medico si è laureato presso la Facoltà di Medicina dell'Università di Selcuk e ha ottenuto il titolo di Professore Associato nel 2016.

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Irfan Cicin

  • 29 anni di esperienza
  • Località: Turchia, Istanbul
  • Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

    Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

    Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Nail Paksoy

  • 15 anni di esperienza
  • accreditamenti:
  • Località: Turchia, Istanbul

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Ercan Ozden

  • 27 anni di esperienza
  • Località: Turchia, Istanbul
  • Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

    Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Atakan Topcu

  • 13 anni di esperienza
  • Località: Turchia, Istanbul
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Ayse Irem Yasin

  • 15 anni di esperienza
  • Località: Turchia, Istanbul
  • Assoc. Prof. Ayşe İrem Yasin, M.D., is a medical oncologist who specializes in solid tumors. Her clinical focus includes breast, lung, gastrointestinal, gynecologic, and urologic cancers. She also treats brain and other CNS tumors, soft tissue sarcomas, head and neck cancers, adenocarcinomas, melanoma, Merkel cell carcinoma, and cancers of unknown primary. She practices at Medipol Acıbadem District Hospital (2025–present). She previously worked at Şişli Etfal Training and Research Hospital (2023–2025).

    She completed a Medical Oncology fellowship at Bezmialem Vakıf University (2019–2022). This followed an Internal Medicine residency at the same institution (2012–2016). Her international experience includes the Breast Cancer Unit at the University of Piemonte Orientale in Novara (2022). She also trained at Basel University Hospital, Cleveland Clinic, and Harvard Medical School. She holds the ESMO Board Certificate (2022).

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Muhammed Mustafa Atci

  • 15 anni di esperienza
  • Località: Turchia, Istanbul
  • Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).

    He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.

    Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.

  • Mostra di più
Visita dal medico
Prezzo su richiesta

Scegliere una clinica all'estero può essere stressante. Da Bookimed, con oltre 800.000 pazienti aiutati, comprendiamo le tue preoccupazioni. Sappiamo come trovare medici affidabili, le migliori opzioni per rapporto qualità-prezzo e soluzioni anche per casi complessi. Siamo qui per guidarti in ogni fase del tuo percorso sanitario.

Yan Matsiivskiy

Capo del team dei coordinatori medici

Oltre 4300+ viaggi assistiti di pazienti

3 anni su Bookimed

278 pazienti da Turkey hanno trovato il loro medico tramite noi questo mese

Come troverai il medico perfetto per te

1

Quiz da 2 minuti

Dicci il tuo obiettivo, budget e tempistiche

2

Abbinamento umano + IA

Il nostro algoritmo trova le corrispondenze, il coordinatore verifica l'idoneità

3

Le tue opzioni pronte

Confronta prezzi, pacchetti, date. Chatta con il tuo coordinatore

Tante opzioni e non sai cosa scegliere?

Il tuo personale Il coordinatore Bookimed ti aiuta a trovare il chirurgo perfetto per le tue esigenze

  • Ti supporta 24/7 in ogni fase
  • Ti aiuta a trovare il medico più adatto e gestisce tutte le comunicazioni con le cliniche
  • Coordina viaggio, alloggio e trasferimenti

Guida il tuo percorso di cura

Coordinatori personali medici qualificati

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk

Come scegliere il medico e la clinica giusti: consigli degli esperti

Quando scegli un medico o una clinica, tieni presente questi punti chiave:
Controlla le credenziali
Verifica le certificazioni di enti come ISAPS, JCI o degli ordini medici pertinenti.
Verifica i tassi di successo
Scegli medici con grande esperienza e comprovata competenza nel trattamento specifico.
Leggi le recensioni dei pazienti
Recensioni reali dei pazienti Bookimed per conoscere la loro esperienza.
Assicura una comunicazione efficace
Scegli cliniche che offrono servizio di traduzione per facilitare il trattamento.
Chiedi informazioni sui servizi
Conferma se il prezzo include servizi come alloggio, trasferimenti locali e assistenza post-trattamento per evitare costi nascosti.

Bookimed Insights: Principali specialisti in Chemioterapia per il cancro al fegato in Turchia (2026)

Bookimed ha coordinato 54043 richieste per Chemioterapia per il cancro al fegato in Turchia, collaborando con 19 specialisti di alto livello. I medici in questa tabella sono selezionati in base alle loro credenziali internazionali, esperienza clinica e risultati dei pazienti. La classifica del 2026 è composta da dati verificati su casi reali e dai programmi attuali delle nostre cliniche partner.
ClassificaMedicoesperienzaBuona scelta perCosa li distingueClinica e posizioneConsulto
#121 anni di esperienzaTesto_dottore: Chemioterapia del cancro al fegatoSpecializzato in oncologia medica con un focus sul tumore del fegato. Classificato terzo in Turchia nell'esame di specializzazione minore e coinvolto in studi clinici internazionali.
Turchia
da $215
#220 anni di esperienzaTumori gastrointestinaliSpecializzato in cancro al fegato con formazione di specializzazione presso l'Istituto Oncologico dell'Università di Hacettepe. Inoltre, ha ricevuto formazione presso il MD Anderson Cancer Center.
Turchia
da $100
#322 anni di esperienzaChemioterapia mirata e immunoterapiaSi concentra su approcci di medicina di precisione per il cancro al fegato, inclusa l'immunoterapia. Certificato ESMO con formazione presso i principali centri internazionali come Mount Vernon.
Turchia
da $215

FAQ

Queste domande frequenti provengono da pazienti reali che cercano assistenza medica tramite Bookimed. Le risposte sono fornite da coordinatori medici esperti e rappresentanti affidabili delle cliniche.

What credentials and experience levels do the top medical oncologists treating liver cancer in Turkey have?

Top medical oncologists for liver cancer in Turkey hold advanced titles like Professor or Associate Professor. They typically possess 20+ years of clinical experience. These specialists maintain international certifications from the European Society for Medical Oncology (ESMO). Many completed fellowships at institutions like MD Anderson or Stanford.

  • Academic leadership: Leading oncologists serve as professors at major faculties like Hacettepe or Marmara University.
  • Global training: Specialists often train at top centers in the USA, UK, or Israel.
  • Research contributions: Top doctors have authored 40+ to 80+ peer-reviewed publications on tumor biology.
  • National ranking: Elite physicians ranked among the top three in national medical oncology proficiency exams.

Bookimed Expert Insight: Data shows that Turkey’s leading liver cancer specialists often hold leadership roles in pioneering medical groups. For instance, Dr. Necdet Uskent at Anadolu Medical Center was a founding member of the Turkish Society of Medical Oncology. This level of seniority indicates they helped establish the national protocols now used to treat complex liver tumors.

Patient Consensus: Patients note that the best results come from doctors who work in multidisciplinary teams with transplant surgeons. They feel more confident when oncologists explain immunotherapy and targeted agents beyond standard chemotherapy. Many found that specialists who trained abroad communicate more clearly in English during consultations.

Do Turkish doctors use a team-based approach when deciding on liver-cancer chemotherapy?

Turkish doctors use a team-based multidisciplinary approach for liver cancer chemotherapy. Specialists such as medical oncologists, hepatobiliary surgeons, and radiologists collaborate through tumor boards. This collective review helps tailor treatment to the patient liver function and cancer stage.

  • Tumor board review: Multiple specialists assess complex cases to coordinate therapy effectively.
  • Individualized protocols: Board-certified oncologists create plans based on genetic and tumor factors.
  • Integrated care paths: Surgeons and medical oncologists work together for potential transplant candidates.
  • Expert evaluation: Doctors emphasize distinguishing primary liver cancer from metastasis during consultation.

Bookimed Expert Insight: Many leading oncologists in Turkey, like Dr. Yesim Yildirim and Dr. Ayse Irem Yasin, hold international certifications from the European Society for Medical Oncology (ESMO). These physicians emphasize precision medicine and often lead tumor boards at JCI-accredited facilities like Anadolu Medical Center. Dr. Bulent Karagoz and Professor Necdet Uskent bring 20+ years of expertise to these teams, ensuring chemotherapy aligns with the latest European and American standards.

Patient Consensus: Patients note that their care is handled by an entire group of specialists rather than just one person. They realized that having surgeons and radiologists weigh in early kept their treatment options open. Many felt much more confident after hearing that a full tumor board reviewed their scans and pathology.

What advanced chemo-delivery techniques do Turkish oncologists prefer for liver cancer?

Turkish oncologists prioritize locoregional delivery techniques like Transarterial Chemoembolization (TACE) and Hepatic Arterial Infusion Chemotherapy (HAIC). These methods concentrate drugs directly within the liver. This targeted approach destroys tumors while sparing healthy tissue from systemic toxicity. Specialists often combine these with precision medicine and immunotherapy.

  • Chemoembolization variations: Doctors use drug-eluting beads (DEB-TACE) for sustained drug release.
  • Infusion systems: Specialists like Dr. Yesim Yildirim utilize catheters for continuous intra-arterial delivery.
  • Precision formulations: Oncologists favor liposomal doxorubicin to minimize cardiotoxicity and systemic side effects.
  • Integrated radioembolization: Multidisciplinary teams often sequence TACE with Yttrium-90 techniques for complex cases.

Bookimed Expert Insight: Turkish oncology centers, such as Anadolu Medical Center, hold International Accreditation for Interventional Oncology Services (IASIOS). This specific certification signifies that the facility meets the highest global standards for complex catheter-based chemo-delivery, a level of specialization not common in general hospitals. Many top oncologists, including Dr. Mustafa Solak and Dr. Ayse Irem Yasin, bring international expertise from institutions like MD Anderson and Harvard Medical School to these specialized units.

Patient Consensus: Patients note that doctors often prioritize procedures like TACE over standard IV drips to keep side effects manageable. They mention feeling a bit tired or nauseous right after the catheter procedure but appreciate that it targets the tumor directly. Many say the recovery is faster than they expected compared to full-body chemotherapy.

What state-of-the-art technologies do Turkish oncologists use alongside chemotherapy to deliver comprehensive care?

Turkish oncologists enhance chemotherapy for liver cancer by integrating precision diagnostics and molecular tumor profiling. Specialists use advanced CyberKnife and Gamma Knife systems to target tumors with robotic accuracy. These technologies allow doctors to treat inoperable lesions while protecting healthy liver tissue for better outcomes.

  • Molecular profiling: Specialists use Next-Generation Sequencing to identify mutations for targeted therapy selection.
  • Interventional procedures: Doctors combine chemotherapy with TACE or chemoembolization for direct regional tumor control.
  • Robotic radiosurgery: Systems like CyberKnife auto-correct for breathing movements to deliver high-dose radiation.
  • Ablation techniques: Microwave and radiofrequency ablation target small lesions without the need for major surgery.

Bookimed Expert Insight: Leading oncology centers in Turkey, such as Anadolu Medical Center, maintain deep affiliations with Johns Hopkins Medicine. This connection gives patients access to international protocols and multidisciplinary tumor boards. Dr. Bulent Karagoz and Dr. Necdet Uskent have over 20+ years of experience and prioritize tumor immunology and targeted biotherapies. Consultations with these specialists start from $215.

Patient Consensus: Patients note that their care feels much more manageable when doctors combine chemotherapy with localized treatments like TACE. They appreciate how modern anti-nausea medications and constant infusion monitoring make the daily experience easier. Many felt more confident after having their case reviewed by a team of different specialists.

How do Turkish oncologists communicate with international patients if I don’t speak Turkish?

Turkish oncologists bridge the language gap through dedicated international departments providing full-time translators and medical coordinators. Most top specialists hold international certifications and completed fellowships in English-speaking countries. Hospitals provide all oncology reports and chemotherapy protocols in the patient's native language to prevent errors.

  • International training: Prof. Yesim Yildirim at Anadolu Medical Center trained in Israel and the UK.
  • Bilingual staff: Dedicated coordinators provide real-time translation during every scan, consultation, and chemotherapy session.
  • Global standards: Specialists like Dr. Mustafa Solak at Hisar Hospital trained at MD Anderson Center.
  • Digital follow-up: Hospitals use telemedicine and messaging for remote chemotherapy adjustments and lab reviews.

Bookimed Expert Insight: Data shows a strong pattern of Turkish oncologists holding dual certifications from European and American boards. For example, Dr. Bulent Karagöz at Anadolu Medical Center and Dr. Eda Tanrikulu have backgrounds in international clinical research and European societies. This global exposure means consultations often occur directly in English, with medical fees like $215 at top clinics often including coordination services.

Patient Consensus: Patients note that WhatsApp is the best way to get quick answers about medication changes or side effects. While treatment logistics are easy to manage, patients recommend bringing written lists of questions to ensure every detail is translated accurately. Many felt much more comfortable after confirming that their specific coordinator would be present for all high-stakes chemotherapy discussions.

Can I get an opinion or treatment plan from a Turkish liver-cancer oncologist before traveling?

You can obtain a formal treatment plan from Turkish liver cancer oncologists before traveling. Leading specialists offer online consultations starting from $100 to $300. These evaluations cover diagnostic reviews and preliminary systemic therapy strategies. Most experts require a complete English medical portfolio for assessment.

  • Virtual consultations: Doctors like Professor Yesim Yildirim and Professor Bulent Karagoz conduct remote sessions.
  • Specialized expertise: Surgeons and oncologists often hold certifications from the European Society of Medical Oncology.
  • Fast timelines: Medical teams typically provide written diagnostic summaries within 48 to 72 hours.
  • Clinical affiliations: Many hospitals partner with institutions like Johns Hopkins Medicine for second opinions.

Bookimed Expert Insight: Data shows that many top oncologists in Turkey, such as Professor Necdet Uskent and Dr. Mustafa Solak, have completed fellowships at major US centers like MD Anderson or Wadley Institutes. This international training ensures their remote plans align with Western standards of care while offering lower costs.

Patient Consensus: Patients emphasize that sending a full packet of high-quality imaging is vital for a useful plan. They note that having a strategy beforehand prevents wasted trips and provides peace of mind. Many realize that remote reviews are valuable even if doctors require final in-person confirmation.